Based on our current findings, we propose that patients with ER+ tumors and high signature expression would not be good candidates for TGF-β antagonist therapy, but that the mere presence of this particular TGF-β tumor-suppressor signature in ER- breast cancer patients would not necessarily be a contraindication for such therapy. This evidence concerns the gene ESR1 and neoplasm.